Use access key #2 to skip to page content.
$5.56 0.00 (0.00%)
10/23/2007 3:58 PM

Bioenvision, Inc. (BIVN)

CAPS Rating:
No stars

A biopharmaceutical company, which focuses upon the acquisition, development and marketing of compounds and technologies for the treatment of cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

BIVN doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

30 Outperforms
14 Underperforms
 

All-Stars

3 Outperforms
4 Underperforms
 

Wall Street

0 Outperforms
1 Underperforms
 

Members bullish on BIVN are also bullish on:

Members bearish on BIVN are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (294)
Suggest a tag

Bioenvision, Inc. At A Glance

Current Price: $5.56
Last Trade Time: 10/23/2007 3:58 PM
Open: $0.00
Previous Close: $5.59
Daily Range: $5.56 - $5.56
52-Week Range: $3.23 - $6.17
Volume: 140
Market Cap: $306.01M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

BIVN VS S&P 500 (SPY)

BIVN 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for BIVN.

Top Bull Pitch

Recs

1

Bioenvision, Inc. (BIVN)

Avatar mbogen (< 20) Submitted: 3/21/07 9:02 AM

has approved drugs in pipeline. could be profitable in 12-18 months.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 14 :   1 2 3 Next »

Show Pitch Replies

Recs

0

 (BIVN)

Avatar 80brown (99.26) Submitted: 6/12/07 12:40 AM : Underperform Start Price: $5.63 BIVN Score: -12.98

Trading at 334% intrinsic value.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BIVN)

Avatar GCD123 (< 20) Submitted: 6/07/07 3:08 PM : Outperform Start Price: $5.68 BIVN Score: 11.86

Oppose the low-ball offer by Genzyme! Go to http://rejectgenzymetenderoffer.com/

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BIVN)

Avatar sabados100 (< 20) Submitted: 5/25/07 12:00 AM : Outperform Start Price: $5.29 BIVN Score: 19.79

This is a five star biotech stock... Genzyme will buy this stock out in the next few months.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (BIVN)

Avatar biotechgod (< 20) Submitted: 5/16/07 7:37 PM : Outperform Start Price: $3.56 BIVN Score: 70.80

Strong balance sheet,very little debt,clofarabine selling well in the EU and in the US. Very Strong sales force of Genzyme selling the product in the US.And lastly pending aproval for Suvus in Egypt for HEP C,and for Elderly AML in the EU for Bioenvisions first label extension.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BIVN)

Avatar Dudeone (78.25) Submitted: 5/14/07 4:37 PM : Outperform Start Price: $3.29 BIVN Score: 83.24

Clofabarine in EU/ROW will make them attractive for takeover I suspect. Watch it kick in a few months time

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 14 :   1 2 3 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackFortisBank 98.32 10/23/06 Underperform NS $5.59-0.54%-5.36%-4.82

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners